The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

And with no admitted fault or failure, I'm delighted that we've also drawn a line under the vast majority of Zantac litigation ... U.S. were key factors, but market shares for both these vaccines ...

Belski is especially bullish on small- and mid-cap equities, calling them “the golden child of the next decade. I think that ...

Notably, GSK’s previously sold antacid Zantac may have caused cancer in some ... From a valuation perspective, GSK, with a $77.0 billion market cap, is already a pharma giant across several ...

Having removed uncertainty by resolving the vast majority of Zantac litigation cases in the ... The Warwickshire-based firm last month scaled back estimates for 2024 due to supply chain disruption ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...

GSK posted a healthy 13% increase in second-quarter sales this morning and raised its forecasts for the year on the back of gains for its cancer and HIV drugs, beating market expectations.

The FTSE 100 index slumped 99.42 points, 1.2%, at 8,025.77. The FTSE 250 closed down 295.73 points, 1.4%, at 20,427.80. The AIM All-Share fell 7.07 points, 1.0%, at 730.86.

GSK did reiterate its financial guidance for the year, however, helped by demand for its cancer and HIV drugs: at constant exchange rates it's still expecting revenue growth of 7% to 9%, core ...